Skip to search formSkip to main contentSkip to account menu

CEM 101

Known as: CEM-101 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
1136 DJ Biedenbach1, HS Sader1, RN Jones1, DJ Farrell1 1JMI Laboratories, North Liberty, Iowa, USA Objective: To evaluate the… 
2008
2008
MBC determinations for CEM-101, telithromycin (TEL) and clarithromycin (CLA) used CLSI methods for 40 strains (6 species groups… 
2008
2008
A worldwide sample of organisms included S. pneumoniae (SPN; 168, 59.3% erythromycin [ERY]-R and 18 MDR-19A strains), M… 
2008
2008
CEM-101 displayed a tight binding to the ribosome from sensitive Gram-negative (E. coli) and Gram-positive (S. aureus) bacteria… 
2008
2008
Results: CEM-101 potency against enterococci showed a bimodal distribution (0.03 and 2 μg/ml), and that activity was 2and ≥ 32… 
2008
2008
Efficacy was evaluated in several infection models. CD-1 female mice were infected IP; CEM-101 or comparators were administered… 
2008
2008
Background: CEM-101, an orally administered macrolide-ketolide for respiratory tract infections (RTI), has potent activity… 
2008
2008
Poster # F1-3972a Study Design and Methodology Results J. Gordon Still, MD, PhD 6340 Quadrangle Dr., Suite 100 Chapel Hill, NC… 
2008
2008
There continues to be a feared scenario of terrorist attacks with aerosolized microorganisms leading to mass infections. Given… 
2008
2008
CEM-101 is a promising new macrolide in development for treating community-acquired (CA) macrolide-resistant and -susceptible…